X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aurobindo Pharma with Lupin Ltd - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AUROBINDO PHARMA vs LUPIN LTD - Comparison Results

AUROBINDO PHARMA    Change

Aurobindo Pharma is one of India's top 5 pharma companies in terms of turnover, and has presence in the generic and Active Pharmaceutical Ingredients (API) segments. The company's robust product portfolio is spread across 6 product areas, including a... More

LUPIN LTD 
   Change

Lupin is a leading pharmaceutical company with a strong presence in anti-infective, cardiovascular and asthma. Apart from having a strong domestic presence, the company markets its products in the regulated markets of the US and Europe and semi-regul... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AUROBINDO PHARMA LUPIN LTD AUROBINDO PHARMA/
LUPIN LTD
 
P/E (TTM) x 18.0 16.6 108.4% View Chart
P/BV x 5.8 3.9 151.2% View Chart
Dividend Yield % 0.4 0.8 44.5%  

Financials

 AUROBINDO PHARMA   LUPIN LTD
EQUITY SHARE DATA
    AUROBINDO PHARMA
Mar-16
LUPIN LTD
Mar-16
AUROBINDO PHARMA/
LUPIN LTD
5-Yr Chart
Click to enlarge
High Rs1,5412,127 72.4%   
Low Rs5821,294 45.0%   
Sales per share (Unadj.) Rs237.5304.1 78.1%  
Earnings per share (Unadj.) Rs33.950.4 67.2%  
Cash flow per share (Unadj.) Rs40.660.7 66.9%  
Dividends per share (Unadj.) Rs2.507.50 33.3%  
Dividend yield (eoy) %0.20.4 53.7%  
Book value per share (Unadj.) Rs120.6243.8 49.5%  
Shares outstanding (eoy) m585.17450.58 129.9%   
Bonus/Rights/Conversions PREF--  
Price / Sales ratio x4.55.6 79.4%   
Avg P/E ratio x31.333.9 92.3%  
P/CF ratio (eoy) x26.228.2 92.8%  
Price / Book Value ratio x8.87.0 125.4%  
Dividend payout %7.414.9 49.6%   
Avg Mkt Cap Rs m621,041770,740 80.6%   
No. of employees `00013.316.4 81.3%   
Total wages/salary Rs m15,50821,077 73.6%   
Avg. sales/employee Rs Th10,457.68,379.6 124.8%   
Avg. wages/employee Rs Th1,167.11,289.0 90.5%   
Avg. net profit/employee Rs Th1,491.61,388.7 107.4%   
INCOME DATA
Net Sales Rs m138,961137,016 101.4%  
Other income Rs m1,6631,877 88.6%   
Total revenues Rs m140,624138,893 101.2%   
Gross profit Rs m32,05637,535 85.4%  
Depreciation Rs m3,9264,635 84.7%   
Interest Rs m2,568446 575.4%   
Profit before tax Rs m27,22534,330 79.3%   
Minority Interest Rs m39-88 -44.6%   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m7,44411,536 64.5%   
Profit after tax Rs m19,82022,707 87.3%  
Gross profit margin %23.127.4 84.2%  
Effective tax rate %27.333.6 81.4%   
Net profit margin %14.316.6 86.1%  
BALANCE SHEET DATA
Current assets Rs m100,01597,790 102.3%   
Current liabilities Rs m74,75953,872 138.8%   
Net working cap to sales %18.232.1 56.7%  
Current ratio x1.31.8 73.7%  
Inventory Days Days10785 126.8%  
Debtors Days Days110121 90.4%  
Net fixed assets Rs m52,35086,379 60.6%   
Share capital Rs m585901 64.9%   
"Free" reserves Rs m67,707105,735 64.0%   
Net worth Rs m70,567109,844 64.2%   
Long term debt Rs m8,47253,739 15.8%   
Total assets Rs m156,994224,378 70.0%  
Interest coverage x11.677.9 14.9%   
Debt to equity ratio x0.10.5 24.5%  
Sales to assets ratio x0.90.6 145.0%   
Return on assets %14.310.3 138.2%  
Return on equity %28.120.7 135.9%  
Return on capital %37.721.2 178.0%  
Exports to sales %51.049.1 104.0%   
Imports to sales %18.87.4 253.2%   
Exports (fob) Rs m70,92767,244 105.5%   
Imports (cif) Rs m26,19310,199 256.8%   
Fx inflow Rs m71,01571,405 99.5%   
Fx outflow Rs m28,79917,807 161.7%   
Net fx Rs m42,21653,598 78.8%   
CASH FLOW
From Operations Rs m17,596-3,690 -476.9%  
From Investments Rs m-13,801-69,434 19.9%  
From Financial Activity Rs m-19858,126 -0.3%  
Net Cashflow Rs m3,597-14,998 -24.0%  

Share Holding

Indian Promoters % 54.1 46.6 116.1%  
Foreign collaborators % 0.0 0.2 -  
Indian inst/Mut Fund % 8.0 11.3 70.4%  
FIIs % 27.7 31.9 86.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.2 10.1 101.0%  
Shareholders   69,601 98,259 70.8%  
Pledged promoter(s) holding % 8.6 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AUROBINDO PHARMA With:   SHASUN PHARMA  WYETH LTD  ABBOTT INDIA  UNICHEM LAB  DR. REDDYS LAB  

Compare AUROBINDO PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Lupin: Decline in US Business Impacts Overall Growth (Quarterly Results Update - Detailed)

May 29, 2017

Currency fluctuation and one time provision impacts operating margins.

Lupin: US Business Drives Growth (Quarterly Results Update - Detailed)

Mar 8, 2017

Lupin has announced its 3QFY17 results. Net sales have grown by 31.5% YoY and net profits have surged by 20.7% YoY. Here is our analysis of the results.

Lupin: Key Products Drive US growth (Quarterly Results Update - Detailed)

Sep 12, 2016

Lupin has announced its 1QFY17results. Net sales have grown by 40% YoY and net profits have surged by 55.1% YoY. Here is our analysis of the results.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AUROBINDO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK AUROBINDO PHARMA

  • Track your investment in AUROBINDO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON AUROBINDO PHARMA

AUROBINDO PHARMA 8-QTR ANALYSIS

COMPARE AUROBINDO PHARMA WITH

MARKET STATS